Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2005

Open Access 01-12-2005 | Research

Hyperresponsiveness to inhaled but not intravenous methacholine during acute respiratory syncytial virus infection in mice

Authors: Rachel A Collins, Rosa C Gualano, Graeme R Zosky, Constance L Atkins, Debra J Turner, Giuseppe N Colasurdo, Peter D Sly

Published in: Respiratory Research | Issue 1/2005

Login to get access

Abstract

Background

To characterise the acute physiological and inflammatory changes induced by low-dose RSV infection in mice.

Methods

BALB/c mice were infected as adults (8 wk) or weanlings (3 wk) with 1 × 105 pfu of RSV A2 or vehicle (intranasal, 30 μl). Inflammation, cytokines and inflammatory markers in bronchoalveolar lavage fluid (BALF) and airway and tissue responses to inhaled methacholine (MCh; 0.001 – 30 mg/ml) were measured 5, 7, 10 and 21 days post infection. Responsiveness to iv MCh (6 – 96 μg/min/kg) in vivo and to electrical field stimulation (EFS) and MCh in vitro were measured at 7 d. Epithelial permeability was measured by Evans Blue dye leakage into BALF at 7 d. Respiratory mechanics were measured using low frequency forced oscillation in tracheostomised and ventilated (450 bpm, flexiVent) mice. Low frequency impedance spectra were calculated (0.5 – 20 Hz) and a model, consisting of an airway compartment [airway resistance (Raw) and inertance (Iaw)] and a constant-phase tissue compartment [coefficients of tissue damping (G) and elastance (H)] was fitted to the data.

Results

Inflammation in adult mouse BALF peaked at 7 d (RSV 15.6 (4.7 SE) vs. control 3.7 (0.7) × 104 cells/ml; p < 0.001), resolving by 21 d, with no increase in weanlings at any timepoint. RSV-infected mice were hyperresponsive to aerosolised MCh at 5 and 7 d (PC200 Raw adults: RSV 0.02 (0.005) vs. control 1.1 (0.41) mg/ml; p = 0.003) (PC200 Raw weanlings: RSV 0.19 (0.12) vs. control 10.2 (6.0) mg/ml MCh; p = 0.001). Increased responsiveness to aerosolised MCh was matched by elevated levels of cysLT at 5 d and elevated VEGF and PGE2 at 7 d in BALF from both adult and weanling mice. Responsiveness was not increased in response to iv MCh in vivo or EFS or MCh challenge in vitro. Increased epithelial permeability was not detected at 7 d.

Conclusion

Infection with 1 × 105 pfu RSV induced extreme hyperresponsiveness to aerosolised MCh during the acute phase of infection in adult and weanling mice. The route-specificity of hyperresponsiveness suggests that epithelial mechanisms were important in determining the physiological effects. Inflammatory changes were dissociated from physiological changes, particularly in weanling mice.
Literature
1.
Glezen P, Denny FW: Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973, 288:498–505.CrossRefPubMed
2.
Glezen WP, Taber LH, Frank AL, Kasel JA: Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140:543–546.PubMed
3.
Openshaw PJ: Immunity and immunopathology to respiratory syncytial virus. The mouse model. Am J Respir Crit Care Med 1995, 152:S59–62.CrossRefPubMed
4.
Harsten G, Prellner K, Lofgren B, Heldrup J, Kalm O, Kornfalt R: Serum antibodies against respiratory tract viruses: a prospective three-year follow-up from birth. J Laryngol Otol 1989, 103:904–908.CrossRefPubMed
5.
Schmidt AC, Johnson TR, Openshaw PJM, Braciale TJ, Falsey AR, Anderson LJ, Wertz GW, Groothuis JR, Prince GA, Melero JA, Graham BS: Respiratory syncytial virus and other pneumoviruses: a review of the international symposium-RSV 2003. Virus Res 2004, 106:1–13.CrossRefPubMed
6.
Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL: Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981, 98:708–715.CrossRefPubMed
7.
Green M, Brayer AF, Schenkman KA, Wald ER: Duration of hospitalization in previously well infants with respiratory syncytial virus infection. Pediatr Infect Dis J 1989, 8:601–605.CrossRefPubMed
8.
Hall CB, Hall WJ, Speers DM: Clinical and physiological manifestations of bronchiolitis and pneumonia. Outcome of respiratory syncytial virus. Am J Dis Child 1979, 133:798–802.CrossRefPubMed
9.
Parrott RH, Kim HW, Arrobio JO, Hodes DS, Murphy BR, Brandt CD, Camargo E, Chanock RM: Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 1973, 98:289–300.PubMed
10.
Moon L, Rahman N, Bhatia K: Australia's children: their health and wellbeing 1998. Canberra, AIHW; 1998:AIHW Catalogue no. PHE 7.
11.
Lemanske RFJ: The childhood origins of asthma (COAST) study. Pediatr Allergy Immunol 2002, 13:38–43.CrossRefPubMed
12.
Prince GA, Horswood RL, Berndt J, Suffin SC, Chanock RM: Respiratory syncytial virus infection in inbred mice. Infect Immun 1979, 26:764–766.PubMedPubMedCentral
13.
Taylor G, Stott EJ, Hughes M, Collins AP: Respiratory syncytial virus infection in mice. Infect Immun 1984, 43:649–655.PubMedPubMedCentral
14.
Anderson JJ, Norden J, Saunders D, Toms GL, Scott R: Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection. J Gen Virol 1990, 71:1561–1570.CrossRefPubMed
15.
van Schaik SM, Enhorning G, Vargas I, Welliver RC: Respiratory syncytial virus affects pulmonary function in BALB/c mice. J Infect Dis 1998, 177:269–276.CrossRefPubMed
16.
Stack AM, Malley R, Saladino RA, Montana JB, MacDonald KL, Molrine DC: Primary respiratory syncytial virus infection: pathology, immune response, and evaluation of vaccine challenge strains in a new mouse model. Vaccine 2000, 18:1412–1418.CrossRefPubMed
17.
Hayes PJ, Scott R, Wheeler J: In vivo production of tumour necrosis factor-alpha and interleukin-6 in BALB/c mice inoculated intranasally with a high dose of respiratory syncytial virus. J Med Virol 1994, 42:323–329.CrossRefPubMed
18.
Peebles RSJ, Sheller JR, Johnson JE, Mitchell DB, Graham BS: Respiratory syncytial virus infection prolongs methacholine-induced airway hyperresponsiveness in ovalbumin-sensitized mice. J Med Virol 1999, 57:186–192.CrossRefPubMed
19.
Stark JM, McDowell SA, Koenigsknecht V, Prows DR, Leikauf JE, Le Vine AM, Leikauf GD: Genetic susceptibility to respiratory syncytial virus infection in inbred mice. J Med Virol 2002, 67:92–100.CrossRefPubMed
20.
Mejias A, Chavez-Bueno S, Rios AM, Saavedra-Lozano J, Fonseca Aten M, Hatfield J, Kapur P, Gomez AM, Jafri HS, Ramilo O: Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 2004, 48:1811–1822.CrossRefPubMedPubMedCentral
21.
Jafri HS, Chavez-Bueno S, Mejias A, Gomez AM, Rios AM, Nassi SS, Yusuf M, Kapur P, Hardy RD, Hatfield et : Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis 2004, 189:1856–1865.CrossRefPubMed
22.
Schwarze J, Hamelmann E, Bradley KL, Takeda K, Gelfand EW: Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest 1997, 100:226–233.CrossRefPubMedPubMedCentral
23.
Cho JY, Miller M, Baek KJ, Castaneda D, Nayar J, Roman M, Raz E, Broide DH: Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion. J Allergy Clin Immunol 2001, 108:697–702.CrossRefPubMed
24.
Bates J, Irvin C, Brusasco V, Drazen J, Fredberg J, Loring S, Eidelman D, Ludwig M, Macklem P, Martin J, Milic-Emili J, Hantos Z, Hyatt R, Lai-Fook S, Leff A, Solway J, Lutchen K, Suki B, Mitzner W, Pare P, Pride N, Sly P: The use and misuse of Penh in animal models of lung disease. Am J Respir Cell Mol Biol 2004, 31:373–374.CrossRefPubMed
25.
Tekkanat KK, Maassab HF, Cho DS, Lai JJ, John A, Berlin A, Kaplan MH, Lukacs NW: IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent. J Immunol 2001, 166:3542–3548.CrossRefPubMed
26.
Graham BS, Bunton LA, Wright PF, Karzon DT: Reinfection of mice with respiratory syncytial virus. J Med Virol 1991, 34:7–13.CrossRefPubMed
27.
Hierholzer JC, Killington RA: Virus isolation and quantitation. In Virology Methods Manual. Edited by: Mahy BWJ and Kangro HO. London, Academic Press; 1996:25–46.CrossRef
28.
Sly PD, Hayden MJ, Petak F, Hantos Z: Measurement of low-frequency respiratory impedance in infants. Am J Resp Crit Care Med 1996, 154:161–166.CrossRefPubMed
29.
Pillow JJ, Korfhagen TR, Ikegami M, Sly PD: Overexpression of TGF-alpha increases lung tissue hysteresivity in transgenic mice. J Appl Physiol 2001, 91:2730–2734.PubMed
30.
Hantos Z, Daroczy B, Suki B, Nagy S, Fredberg JJ: Input impedance and peripheral inhomogeneity of dog lungs. J Appl Physiol 1992, 72:168–178.CrossRefPubMed
31.
Hirai T, McKeown KA, Gomes RFM, Bates JHT: Effects of lung volume on lung and chest wall mechanics in rats. J Appl Physiol 1999, 86:16–21.PubMed
32.
Sakai H, Ingenito EP, Mora R, Abbay S, Cavalcante FSA, Lutchen KR, Suki B: Hysteresivity of the lung and tissue strip in the normal rat: effects of heterogeneities. J Appl Physiol 2001, 91:737–747.PubMed
33.
Sly PD, Collins RA, Thamrin C, Turner DJ, Hantos Z: Volume dependence of airway and tissue impedances in mice. J Appl Physiol 2003, 94:1460–1466.CrossRefPubMed
34.
Brown RH, Mitzner W: Airway response to deep inspiration: role of inflation pressure. J Appl Physiol 2001, 91:2574–2578.PubMed
35.
Patterson CE, Rhoades RA, Garcia JG: Evans blue dye as a marker of albumin clearance in cultured endothelial monolayer and isolated lung. J Appl Physiol 1992, 72:865–873.CrossRefPubMed
36.
Tulic MK, Wale JL, Holt PG, Sly PD: Modification of the inflammatory response to allergen challenge after exposure to bacterial lipopolysaccharide. Am J Resp Cell Mol Biol 2000, 22:604–612.CrossRef
37.
Bell SC, Rynell AC, Matheson MJ, Finnimore AJ, Berend N: Inhaled FMLP increases microvascular permeability in the rabbit trachea. J Appl Physiol 1993, 74:1337–1341.PubMed
38.
Bozanich EM, Collins RA, Thamrin C, Hantos Z, Sly PD, Turner DJ: Developmental changes in airway and tissue mechanics in mice. J Appl Physiol 2005, 99:108–113.CrossRefPubMed
39.
Stark JM, Khan AM, Chiappetta CL, Xue H, Alcorn JL, Colasurdo GN: Immune and functional role of nitric oxide in a mouse model of respiratory syncytial virus infection. J Infect Dis 2005, 191:387–395.CrossRefPubMed
40.
Dakhama A, Park JW, Taube C, El Gazzar M, Kodama T, Miyahara N, Takeda K, Kanehiro A, Balhorn A, Joetham A, Loader JE, Larsen GL, Gelfand EW: Alteration of airway neuropeptide expression and development of airway hyperresponsiveness following respiratory syncytial virus infection. Am J Physiol Lung Cell Mol Physiol 2005, 288:L761–770.CrossRefPubMed
41.
Holtzman MJ, Hahn HL, Sasaki K, Skoogh BE, Graf PD, Fabbri LM, Nadel JA: Selective effect of general anesthetics on reflex bronchoconstrictor responses in dogs. J Appl Physiol 1982, 53:126–133.PubMed
42.
Skoogh BE, Holtzman MJ, Sheller JR, Nadel JA: Barbiturates depress vagal motor pathway to ferret trachea at ganglia. J Appl Physiol 1982, 53:253–257.PubMed
43.
Colasurdo GN, Hemming VG, Prince GA, Loader JE, Graves JP, Larsen GL: Human respiratory syncytial virus affects nonadrenergic noncholinergic inhibition in cotton rat airways. Am J Physiol Lung Cell Mol Physiol 1995, 268:L1006–11.
44.
Chiba Y, Ueno A, Sakai H, Misawa M: Hyperresponsiveness of bronchial but not tracheal smooth muscle in a murine model of allergic bronchial asthma. Inflamm Res 2004, 53:636–642.CrossRefPubMed
45.
Coyle AJ, Mitzner W, Irvin CG: Cationic proteins alter smooth muscle function by an epithelium-dependent mechanism. J Appl Physiol 1993, 74:1761–1768.PubMed
46.
Coyle AJ, Ackerman SJ, Irvin CG: Cationic proteins induce airway hyperresponsiveness dependent on charge interactions. Am Rev Respir Dis 1993, 147:896–900.CrossRefPubMed
47.
Uchida DA, Ackerman SJ, Coyle AJ, Larsen GL, Weller PF, Freed J, Irvin CG: The effect of human eosinophil granule major basic protein on airway responsiveness in the rat in vivo. A comparison with polycations. Am Rev Respir Dis 1993, 147:982–988.CrossRefPubMed
48.
Lee CG, Yoon HJ, Zhu Z, Link H, Wang Z, Gwaltney JMJ, Landry M, Elias JA: Respiratory syncytial virus stimulation of vascular endothelial cell growth factor/vascular permeability factor. Am J Respir Cell Mol Biol 2000, 23:662–669.CrossRefPubMed
49.
Kilani MM, Mohammed KA, Nasreen N, Hardwick JA, Kaplan MH, Tepper RS, Antony VB: Respiratory syncytial virus causes increased bronchial epithelial permeability. Chest 2004, 126:186–191.CrossRefPubMed
50.
Saria A, Lundberg JM: Evans blue fluorescence: quantitative and morphological evaluation of vascular permeability in animal tissues. J Neurosci Methods 1983, 8:41–49.CrossRefPubMed
51.
Hills BA: An alternative view of the role(s) of surfactant and the alveolar model. J Appl Physiol 1999, 87:1567–1583.PubMed
52.
53.
Hills BA, Chen Y: Suppression of neural activity of bronchial irritant receptors by surface-active phospholipid in comparison with topical drugs commonly prescribed for asthma. Clin Exp Allergy 2000, 30:1266–1274.CrossRefPubMed
54.
van Schaik SM, Vargas I, Welliver RC, Enhorning G: Surfactant dysfunction develops in BALB/c mice infected with respiratory syncytial virus. Pediatr Res 1997, 42:169–173.CrossRefPubMed
55.
Barnes NC, Piper PJ, Costello JF: Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax 1984, 39:500–504.CrossRefPubMedPubMedCentral
56.
Drazen JM, Austen KF, Lewis RA, Clark DA, Goto G, Marfat A, Corey EJ: Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. PNAS 1980, 77:4354–4358.CrossRefPubMedPubMedCentral
57.
Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M: Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982, 126:449–451.PubMed
58.
Narumiya S, Sugimoto Y, Ushikubi F: Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999, 79:1193–1226.PubMed
59.
Morrison KJ, Gao Y, Vanhoutte PM: Epithelial modulation of airway smooth muscle. American Journal of Physiology 1990, 258:L254–262.PubMed
60.
Mathe AA, Hedqvist P: Effect of prostaglandins F2 alpha and E2 on airway conductance in healthy subjects and asthmatic patients. Am Rev Respir Dis 1975, 111:313–320.PubMed
61.
62.
Martin JG, Suzuki M, Maghni K, Pantano R, Ramos-Barbon D, Ihaku D, Nantel F, Denis D, Hamid Q, Powell WS: The immunomodulatory actions of prostaglandin E2 on allergic airway responses in the rat. J Immunol 2002, 169:3963–3969.CrossRefPubMed
63.
Tilley SL, Hartney JM, Erikson CJ, Jania C, Nguyen M, Stock J, McNeisch J, Valancius C, Panettieri RAJ, Penn RB, Koller BH: Receptors and pathways mediating the effects of prostaglandin E2 on airway tone. Am J Physiol Lung Cell Mol Physiol 2003, 284:L599–606.CrossRefPubMed
64.
Ushikubi F, Hirata M, Narumiya S: Molecular biology of prostanoid receptors; an overview. J Lipid Mediat Cell Signal 1995, 12:343–359.CrossRefPubMed
65.
Katsuyama M, Nishigaki N, Sugimoto Y, Morimoto K, Negishi M, Narumiya S, Ichikawa A: The mouse prostaglandin E receptor EP2 subtype: cloning, expression, and northern blot analysis. FEBS Lett 1995, 372:151–156.CrossRefPubMed
66.
Volovitz B, Welliver RC, De Castro G, Krystofik DA, Ogra PL: The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. Pediatr Res 1988, 24:504–507.CrossRefPubMed
67.
van Schaik SM, Tristram DA, Nagpal IS, Hintz KM, Welliver RC, Welliver RC: Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 1999, 103:630–636.CrossRefPubMed
68.
Sznajer Y, Westcott JY, Wenzel SE, Mazer B, Tucci M, Toledano BJ: Airway eicosanoids in acute severe respiratory syncytial virus bronchiolitis. J Pediatr 2004, 145:115–118.CrossRefPubMed
Metadata
Title
Hyperresponsiveness to inhaled but not intravenous methacholine during acute respiratory syncytial virus infection in mice
Authors
Rachel A Collins
Rosa C Gualano
Graeme R Zosky
Constance L Atkins
Debra J Turner
Giuseppe N Colasurdo
Peter D Sly
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2005
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-6-142

Other articles of this Issue 1/2005

Respiratory Research 1/2005 Go to the issue

Research

Characterization of lymphocyte populations in nonspecific interstitial pneumonia*

Research

The crucial role of particle surface reactivity in respirable quartz-induced reactive oxygen/nitrogen species formation and APE/Ref-1 induction in rat lung

Research

Occupational risk of tuberculosis transmission in a low incidence area

Research

Surfactant Protein-A inhibits Aspergillus fumigatus-induced allergic T-cell responses

Research

Airway epithelial cell tolerance to Pseudomonas aeruginosa

Research

Extent of exposure to environmental tobacco smoke (ETS) and its dose-response relation to respiratory health among adults
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits